推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 日前，云南省科技廳發(fā)布消息稱“預(yù)計(jì)未來(lái)3年內(nèi)，第一項(xiàng)三七國(guó)際標(biāo)準(zhǔn)將誕生”。
2014年，省科技廳支持昆明理工大學(xué)聯(lián)合澳門(mén)科技大學(xué)、中國(guó)中醫(yī)科學(xué)院中藥資源中心研究制定的《三七種子種苗》和《三七藥材》2項(xiàng)國(guó)際標(biāo)準(zhǔn)，得到了國(guó)際標(biāo)準(zhǔn)化組織(iso)澳大利亞、加拿大、新加坡、泰國(guó)等9個(gè)成員國(guó)投票支持，獲得iso/tc249國(guó)際立項(xiàng)，目前已正式進(jìn)入iso標(biāo)準(zhǔn)制定程序。
傳統(tǒng)中醫(yī)藥與西方現(xiàn)代醫(yī)學(xué)體系之間存在較大差異，由于缺乏系統(tǒng)的現(xiàn)代科學(xué)臨床研究數(shù)據(jù)支撐，同時(shí)又難以用現(xiàn)代醫(yī)學(xué)理論做出科學(xué)的表述，直接阻礙著中藥產(chǎn)品進(jìn)入國(guó)際市場(chǎng)。更重要的是，中藥目前還沒(méi)有國(guó)際認(rèn)可的統(tǒng)一的質(zhì)量標(biāo)準(zhǔn)，這直接導(dǎo)致中藥難以走出國(guó)門(mén)。去年，國(guó)際標(biāo)準(zhǔn)化組織(iso)發(fā)布了《人參種子種苗》國(guó)際標(biāo)準(zhǔn)，成為中醫(yī)藥界的焦點(diǎn)事件。
省科技廳有關(guān)負(fù)責(zé)人表示，三七國(guó)際標(biāo)準(zhǔn)的誕生，將對(duì)推進(jìn)三七的國(guó)際化進(jìn)程，打開(kāi)國(guó)際市場(chǎng)，帶動(dòng)云藥產(chǎn)業(yè)跨越發(fā)展具有十分重要的作用和深遠(yuǎn)的戰(zhàn)略意義。
